ACADIA Pharmaceuticals Inc.

LSE:0A4W Stock Report

Market Cap: US$2.5b

ACADIA Pharmaceuticals Past Earnings Performance

Past criteria checks 3/6

ACADIA Pharmaceuticals has been growing earnings at an average annual rate of 24.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 18.4% per year. ACADIA Pharmaceuticals's return on equity is 5.9%, and it has net margins of 3.4%.

Key information

24.5%

Earnings growth rate

27.0%

EPS growth rate

Biotechs Industry Growth11.5%
Revenue growth rate18.4%
Return on equity5.9%
Net Margin3.4%
Next Earnings Update06 Nov 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How ACADIA Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

LSE:0A4W Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24891314340
31 Mar 24814-24130
31 Dec 23726-614070
30 Sep 23632-1493990
30 Jun 23551-1113800
31 Mar 23520-1463740
31 Dec 22517-2163690
30 Sep 22512-2173710
30 Jun 22512-2053740
31 Mar 22493-2143810
31 Dec 21484-1683960
30 Sep 21474-1924110
30 Jun 21463-2624110
31 Mar 21458-2603980
31 Dec 20442-2823890
30 Sep 20419-2683600
30 Jun 20393-2253510
31 Mar 20366-2383350
31 Dec 19339-2353260
30 Sep 19300-2483080
30 Jun 19264-2682960
31 Mar 19238-2762980
31 Dec 18224-2452660
30 Sep 18208-2492580
30 Jun 18185-2522590
31 Mar 18158-2562500
31 Dec 17125-2892550
30 Sep 1793-2992460
30 Jun 1763-3062350
31 Mar 1733-3092250
31 Dec 1617-2711860
30 Sep 165-2381510
30 Jun 160-2061210
31 Mar 160-174920
31 Dec 150-164790
30 Sep 150-147670
30 Jun 150-133540
31 Mar 150-115410
31 Dec 140-92330
30 Sep 140-76270
30 Jun 140-62220
31 Mar 141-50170
31 Dec 131-38130

Quality Earnings: 0A4W has high quality earnings.

Growing Profit Margin: 0A4W became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 0A4W has become profitable over the past 5 years, growing earnings by 24.5% per year.

Accelerating Growth: 0A4W has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 0A4W has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: 0A4W's Return on Equity (5.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies